Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and COPD Exacerbations in Patients With Moderate to Very Severe COPD (ASCENT COPD)

Trial Profile

Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and COPD Exacerbations in Patients With Moderate to Very Severe COPD (ASCENT COPD)

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 21 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aclidinium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ASCENT; ASCENT COPD
  • Sponsors Actavis; AstraZeneca; Forest Laboratories
  • Most Recent Events

    • 21 Oct 2019 According to a Circassia media release, results have been presented at Respiratory Educational Reception at the American College of Chest Physicians CHEST Annual Meeting 2019.
    • 07 May 2019 Results published in the JAMA: the Journal of the American Medical Association
    • 01 Apr 2019 According to a Circassia media release, the company announces the US Food and Drug Administration (FDA) has approved Duaklir Pressair for the maintenance treatment of chronic obstructive pulmonary disease. The approval is based on a broad clinical database, including data from three phase III studies, ACLIFORM, AUGMENT, AMPLIFY and phase IV ASCENT study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top